Biblio

Author Title [ Type

] Year

Filters: Author is Malagola, Michele [Clear All Filters]

Journal Article

Zizioli D, Mione M, Varinelli M, Malagola M, Bernardi S, Alghisi E, Borsani G, Finazzi D, Monti E, Presta M, et al. Zebrafish disease models in hematology: Highlights on biological and translational impact. Biochim Biophys Acta Mol Basis Dis. 2018.

Lougaris V, Malagola M, Baronio M, Morello E, Gazzurelli L, Benvenuto A, Palumbo L, Moratto D, Girelli MFederica, Chiarini M, et al. Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion. Clin Immunol. 2020:108589.

Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, et al. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Societ. Biol Blood Marrow Transplant. 2019.

Morello E, Roversi S, Brambilla G, Signorini L, Lorenzoni M, Andreoli M, Bernardi S, Malagola M, Farina M, Radici V, et al. Nutritional strategies to improve VRE control. Transplant Cell Ther. 2024.

Malagola M, Bernardi S, Polverelli N, Russo D. Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?. Br J Haematol. 2020.

Malagola M, Iurlo A, Bucelli C, Abruzzese E, Bonifacio M, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, et al. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan. Clin Lymphoma Myeloma Leuk. 2024.

Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, et al. GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. Transplant Cell Ther. 2021.

Bernardi S, Malagola M, Polverelli N, Russo D. Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?. Acta Haematol. 2020:1-2.

Russo D, Martinelli G, Malagola M, Skert C, Soverini S, Iacobucci I, De Vivo A, Testoni N, Castagnetti F, Gugliotta G, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013.

Malagola M, Greco R, Cheikh JEl. Editorial: 50 years of BMT: conditioning regimens and early complications after transplantation. Front Oncol. 2024;14:1369573.

Malagola M, Radici V, Farina M, Pellizzeri S, Spoldi F, Morello E, Polverelli N, Buttini EAccorsi, Bernardi S, Re F, et al. Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2023.

Malagola M, Radici V, Farina M, Pellizzeri S, Spoldi F, Morello E, Polverelli N, Buttini EAccorsi, Bernardi S, Re F, et al. CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2023.

Malfona F, Tanasi I, Piccini M, Papayannidis C, Federico V, Mancini V, Roncoroni E, Todisco E, Bianchi S, Ciotti G, et al. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study. Haematologica. 2023.